Aclarion, Inc. (NASDAQ:ACON) is a healthcare technology company pioneering the use of advanced biomarkers and augmented intelligence to transform how physicians diagnose and treat chronic low back pain. Headquartered in Broomfield, Colorado, the company has developed a revolutionary software-as-a-service platform called Nociscan — the first evidence-supported solution designed to noninvasively identify which spinal discs are the true sources of a patient’s pain. By combining magnetic resonance spectroscopy (MRS) data with proprietary AI algorithms, Nociscan converts biochemical information from the spine into clear, objective biomarkers that distinguish between painful and non-painful discs. This diagnostic clarity enables physicians to create more accurate, personalized treatment plans and reduce the risk of unnecessary or failed surgeries, addressing one of the most costly and prevalent health challenges in the world.
The company’s mission is rooted in solving a long-standing problem in spine care — the lack of precise tools for determining the source of discogenic pain. For decades, conventional imaging technologies like MRI and CT scans have revealed structural abnormalities but have been unable to pinpoint which disc is actually responsible for a patient’s pain. This diagnostic uncertainty often leads to trial-and-error treatment approaches, with many patients undergoing costly and invasive surgeries that fail to provide relief. Aclarion’s Nociscan platform eliminates that ambiguity by integrating biochemical analysis into the diagnostic process, bridging the gap between imaging and clinical decision-making. With more than 266 million people worldwide suffering from chronic low back pain, the company is addressing an enormous unmet medical need that has direct implications for healthcare efficiency, patient quality of life, and global medical spending.
Aclarion’s innovation lies in its ability to combine sophisticated imaging science with cloud-based analytics to deliver actionable data directly into physicians’ hands. The company’s proprietary algorithms interpret spectroscopic readings to produce intuitive, evidence-based visualizations that guide clinical judgment. This approach not only enhances diagnostic accuracy but also aligns with the broader trend in healthcare toward precision medicine and data-driven care. By providing physicians with reproducible and quantitative insights, Aclarion empowers them to move beyond subjective interpretation and deliver targeted, effective interventions for patients suffering from chronic spine disorders.
Under the leadership of CEO Brent Ness, Aclarion has positioned itself at the forefront of the digital health revolution. The company’s technology has been recognized by industry leaders and institutions for its potential to redefine clinical diagnostics. In 2025, Aclarion was named a finalist in the Rising Star – Clinical Diagnostic Device category at the prestigious Digital Health Hub Foundation Awards at HLTH, selected from more than 1,800 submissions. This recognition underscores Aclarion’s role as a pioneer in the convergence of artificial intelligence, imaging, and personalized medicine, highlighting its dedication to improving healthcare speed, accuracy, and accessibility. Ness emphasized that this milestone reflects the company’s unwavering mission to make Nociscan the global standard for identifying the source of chronic low back pain and to bring relief to millions of patients worldwide.
Beyond its flagship product, Aclarion’s platform represents a scalable model for innovation in healthcare diagnostics. Its software-as-a-service (SaaS) structure enables seamless integration into existing hospital and clinic workflows, requiring minimal infrastructure investment while allowing real-time data analysis and physician collaboration. The company’s business model supports long-term growth through recurring revenues, reimbursement opportunities, and strategic partnerships with spine care providers, medical device companies, and payer networks. As the company expands its clinical footprint through trials such as CLARITY — designed to validate Nociscan’s impact on surgical outcomes — it continues to build a foundation for broader adoption across both domestic and international markets.
Aclarion’s work also reflects a broader mission beyond business success: advancing patient-centered innovation that merges science and compassion. The company’s pursuit of diagnostic precision is transforming the standard of care for one of the world’s most debilitating conditions. By empowering clinicians with actionable insights, reducing unnecessary surgeries, and improving treatment outcomes, Aclarion is setting a new benchmark for how technology can enhance medical practice. As global healthcare systems increasingly adopt AI-driven solutions to reduce costs and improve outcomes, Aclarion stands out as a leader in applying these technologies to one of the most urgent and widespread health challenges of our time.
CHECK THIS OUT: Tiziana (TLSA) Surges 143% in 2025 and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
Turning MRI Signals Into Actionable Biomarkers
Aclarion’s breakthrough lies in its ability to transform magnetic resonance spectroscopy (MRS) signals into objective biomarkers associated with disc pain. Traditional MRI scans show structural abnormalities but cannot determine which discs are actually causing pain. Nociscan bridges this diagnostic gap by applying AI-based analytics to generate a biochemical map of the lumbar spine, distinguishing between painful and non-painful discs. This insight enables physicians to create personalized treatment plans, reducing unnecessary surgeries and improving patient outcomes. With more than 266 million people globally suffering from chronic low back pain, Nociscan’s potential impact extends far beyond the radiology suite — it represents a major step forward in personalized medicine, precision diagnostics, and healthcare cost reduction.
Global Recognition for Innovation in Digital Health
In October 2025, Aclarion achieved a major milestone when it was named a finalist in the Rising Star – Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH, one of the industry’s most prestigious events. This recognition is a validation of the company’s technological leadership and its commitment to transforming the global standard for spine care. Competing against more than 1,800 submissions, Aclarion’s selection as a finalist underscores the growing recognition of Nociscan’s clinical relevance and the scalability of its software-as-a-service (SaaS) model. The awards celebrate organizations driving innovation and equity in healthcare, reinforcing Aclarion’s position as a trailblazer in digital health diagnostics.
Leadership and Vision Driving the Next Generation of Diagnostics
Aclarion’s CEO, Brent Ness, emphasized that this achievement reflects the team’s long-standing mission and unwavering vision: “We are truly honored to be recognized as a finalist by the Digital Health Hub Foundation, which is a testament not only to the innovation of our team today but also to the vision and determination that have guided Aclarion from the very beginning.” Ness reiterated that Aclarion’s goal is to make Nociscan the gold standard for identifying the true source of back pain, making accurate diagnosis accessible to millions worldwide.
Combining AI and Imaging Biomarkers for Precision Medicine
The company’s unique combination of AI-driven analytics and imaging biomarkers sets it apart from conventional imaging providers and diagnostic firms. Its proprietary algorithms are trained on extensive data sets to interpret MRS readings with precision, offering physicians reproducible, evidence-supported insights unavailable through standard imaging. This transforms the traditional diagnostic workflow from an interpretive process into a quantifiable one, giving surgeons a clearer understanding of where pain originates — and how best to treat it. The implications extend not only to clinical decision-making but also to payer efficiency, as improved diagnostic accuracy can reduce unnecessary procedures and healthcare costs.
Building Momentum Through Clinical Trials and Partnerships
Aclarion’s inclusion in the Digital Health Hub Foundation Awards marks another key step in its broader strategy to scale commercial adoption. As the company continues its CLARITY clinical trial, aimed at validating the impact of Nociscan on surgical outcomes, it is simultaneously expanding partnerships with hospitals, research centers, and spine clinics across the United States and Europe. By aligning itself with major institutions, Aclarion is building a strong foundation for payer reimbursement, regulatory recognition, and large-scale market integration.
The Convergence of AI, Imaging, and Healthcare Innovation
The company’s progress also reflects broader trends in healthcare — particularly the convergence of AI, imaging, and data-driven diagnostics. In a landscape increasingly defined by precision medicine and outcome-based care, Aclarion’s Nociscan technology represents a critical link between patient biology and physician decision-making. The system’s software-as-a-service model makes it scalable, providing hospitals and clinics with an easily integrated solution without the need for extensive infrastructure investment. This approach not only accelerates adoption but also creates recurring revenue streams, giving Aclarion a powerful combination of clinical value and financial sustainability.
Redefining the Future of Spinal Diagnostics
By transforming diagnostic imaging into a quantitative science, Aclarion is positioning itself at the intersection of biotechnology, artificial intelligence, and clinical medicine. The company’s innovation aligns perfectly with the healthcare sector’s shift toward predictive analytics and personalized care, where data is the ultimate differentiator. Its recognition at HLTH 2025 signifies not just a milestone for Aclarion, but a broader acknowledgment that the future of diagnostics lies in AI-enhanced, biomarker-driven precision tools.
Aclarion’s Mission: Bringing Clarity and Hope to Millions
With strong scientific leadership, a well-defined clinical roadmap, and increasing validation from both peers and industry experts, Aclarion Inc. stands at the forefront of one of healthcare’s most promising frontiers. As it continues to expand the reach of Nociscan, the company’s mission remains clear — to bring objective clarity to one of medicine’s most misunderstood conditions and to help millions of patients reclaim their lives from chronic pain.
READ ALSO: Saudi Arabia Wants CEL-SCI (CVM)’s Multikine Now! and Aligos Therapeutics (ALGS) Doubles Cash to $122.9M.
